CRISPR Therapeutics (CRSP)
(Real Time Quote from BATS)
$54.88 USD
+0.32 (0.59%)
Updated Jul 22, 2024 01:10 PM ET
1-Strong Buy of 5 1
F Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRSP 54.88 +0.32(0.59%)
Will CRSP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
Here's Why CRISPR Therapeutics AG (CRSP) Gained But Lagged the Market Today
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
Other News for CRSP
3 Gene Editing Stocks That Could Grow Your Wealth
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Crispr Therapeutics call volume above normal and directionally bullish
Blue Chips, Small Caps Extending Their Breakout
CRISPR Therapeutics (CRSP) Shares Cross Above 200 DMA